13P The landscape of human epidermal growth factor receptor 2 (HER2) expression in gynaecologic tumors (GynT)
HER2-targeted therapies have improved outcomes in multiple solid tumors and are under investigation in GynT, where reported HER2 expression is variable and, despite associations with aggressive disease, its clinical significance remains unclear.
Authors
- R. Fasani
- P.G. Nuciforo
- R. Mazzeo
- D. Montanari
- C. García Duran
- L. Fariñas Madrid
- L. Caritá
- J. Jimenez
- G Villacampa
- A. Oaknin
- D. Garcia Illescas
- I. Giannubilo
Institutions
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Vall d'Hebron Institut de Recerca (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.108038
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00